Spearhead Capital Advisors’s Twist Bioscience TWST Stock Holding History

Spearhead Capital Advisors’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,279	Closed	-$211K	–	211
2022 Q1	$211K	Buy	4,279 +1,337	+45%	+$74.1K	0.03%	185
2021 Q4	$228K	Buy	2,942 +44	+2%	+$4.52K	0.03%	164
2021 Q3	$310K	Sell	2,898 -22	-0.8%	-$2.52K	0.04%	149
2021 Q2	$389K	Buy	2,920 +413	+16%	+$48K	0.05%	150
2021 Q1	$311K	Buy	+2,507	New	+$381K	0.05%	162

Other funds holding TWST

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Spearhead Capital Advisors's TWST Position: Q2 2022 in Review

Spearhead Capital Advisors sold out of Twist Bioscience (TWST) in Q2 2022, closing a stake of 4,279 shares — an estimated $211K sold.

Spearhead Capital Advisors first reported a position in TWST in Q1 2021 and held it in 5 quarters. The position peaked at $389K in Q2 2021. 205 funds tracked by Wall St. Rank hold TWST as of Q2 2022.

Spearhead Capital Advisors reported no remaining Twist Bioscience position as of Q2 2022 after selling out during the quarter.
Spearhead Capital Advisors sold 4,279 Twist Bioscience shares in Q2 2022, an estimated $211K.
Spearhead Capital Advisors first reported a position in Twist Bioscience in Q1 2021 and held it in 5 quarters.
Spearhead Capital Advisors's Twist Bioscience position peaked at $389K in Q2 2021.
205 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2022.

Based on Spearhead Capital Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.